参考文献
(在框内滑动手指即可浏览)
[1] Gambardella C,Offi C,Patrone R,et al.Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?[J].BMC Endocr Disord,2019,19(1):45.
[2] Costante G,Meringolo D.Calcitonin as a biomarker of C cell disease: recent achievements and current challenges[J].Endocrine,2020,67(2): 273-280.
[3] Danila R,Livadariu R,Branisteanu D.Calcitonin revisited in 2020[J].Acta Endocrinol (Buchar),2019,15(4):544-548.
[4] Kwon H,Kim WG,Choi YM,et al.A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma[J].Clin Endocrinol (Oxf),2015,82(4):598-603.
[5] Allelein S,Ehlers M,Morneau C,et al.Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer[J].Horm Metab Res,2018,50(1):23-28.
[6] Niederle MB,Scheuba C,Riss P,et al.Early diagnosis of medullary thyroid cancer: are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays?[J].Thyroid,2020,30(7):974-984.
[7] Haugen BR,Alexander EK,Bible KC,et al.2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid Cancer[J]. Thyroid,2015,26(1):1-133.
[8] Wells SAJr,Asa SL,Dralle H,et al.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J].Thyroid,2015,25(6):567-610.
[9] Unluhizarci K,Akgun H,Oz B,et al.Patients with papillary thyroid carcinoma associated with high stimulated serum calcitonin levels[J].Endocrinology,2017,2017(1):1530.
[10] Brutsaert EF,Gersten AJ,Tassler AB,et al.Medullary thyroid cancer with undetectable serum calcitonin[J].J Clin Endocrinol Metab,2015,100(2):337-341.
[11] Turk Y,Makay O,Ozdemir M,et al.Routine calcitonin measurement in nodular thyroid disease management: is it worthwhile?[J].Ann Surg Treat Res,2017,92(4):173-178.
[12] 殷德涛,张高朋,李红强,等.甲状腺结节患者常规行血清降钙素检查对早期发现甲状腺髓样癌的临床价值[J].中国普通外科杂志,2018,27(5):541-546.
[13] Opsahl EM,Akslen LA,Schlichting E,et al.Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in norway: a nationwide population-based study[J].Eur Thyroid J,2019,8(1):31-40.
[14] Madsen LW,Knauf JA,Gotfredsen CF,et al.GLP-1 receptor agonists and the thyroid: c-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation[J].Endocrinology,2012,153(3):1538-1547.
[15] Hegedus L,Sherman SI,Tuttle RM,et al.No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial[J].Diabetes Care,2017,41(3):620-622.
[16] Bethel MA,Patel RA,Thompson VP,et al.Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL)[J].Diabetes Care,2019,42(6):1075-1080.
[17] Machens A,Dralle H,Dralle H.Biomarker-based risk stratification for previously untreated medullary thyroid cancer[J].J Clin Endocrinol Metab,2010,95(6):2655-2663.
[18] Guo QQ,Zhang SH,Niu LJ,et al.Comprehensive evaluation of medullary thyroid carcinoma before surgery[J].Chin Med J (Engl),2019,132(7):834-841.
[19] Siironen P,Hagstrom J,Maenpaa H,et al.Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma[J].Acta Oncol,2016,55(3):357-364.
[20] Machens A,Lorenz K,Dralle H,et al.Prediction of biochemical cure in patients with medullary thyroid cancer[J].Br J Surg,2020,107(6):695-704.
[21] 中国抗癌协会甲状腺癌专业委员会(CATO).甲状腺癌血清标志物临床应用专家共识(2017版)[J].中国肿瘤临床,2018,45(1): 7-13.
[22] Raue F,Frank-Raue K.Long-term follow-up in medullary thyroid carcinoma[J].Recent Results Cancer Res,2015,204(2015):207-225.
[23] Rowland KJ,Jin LX,Moley JF,et al.Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis[J].Ann Surg Oncol,2015,22(1):96-102.
[24] Andrade F,Rondeau G,Boucai L,et al.Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer[J].Arch Endocrinol Metab,2019,63(2):137-141.
[25] Machens A,Lorenz K,Dralle H,et al.Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer[J].Br J Surg,2019,106(4):412-418.
[26] Barbet J,Campion L,Kraeber-Bodéré F,et al.Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma[J].J Clin Endocrinol Metab,2005,90(11):6077-6084.
[27] Hassan A,Siddique M,Riaz S,et al.Medullary thyroid carcinoma: prognostic variables and tumour markers affecting survival[J]. J Ayub Med Coll Abbottabad,2018,30(suppl 4):627-632.
[28] Miyauchi A,Kudo T,Kihara M,et al.Spontaneous deceleration and acceleration of growth rate in medullary thyroid carcinomas suggested by changes in calcitonin doubling times over long-term surveillance[J].World J Surg,2019,43(2):504-512.
[29] Chen L,Sun W,Qian K,et al.High ratio of early postoperative calcitonin to preoperative calcitonin could be a novel indicator of poor prognosis in patients with biochemical incomplete responses in sporadic medullary thyroid cancer[J].Endocr Pract,2020.doi:10.4158/EP-2019-0404.[Epub ahead of print].
[30] Werner RA,Schmid JS,Muegge DO,et al.Prognostic value of serum tumor markers in medullary thyroid cancer patients undergoing vandetanib treatment[J].Medicine (Baltimore),2015,94(45):e2016.